Lupus Erythematosus, Discoid Clinical Trial
Official title:
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if deucravacitinib is biologically active and potentially effective in the treatment of participants with moderate to severe DLE/SCLE with or without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
| Completed |
NCT01858792 -
A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
|
N/A | |
| Withdrawn |
NCT00222183 -
Cutaneous Lupus Erythematosus and Elidel
|
N/A | |
| Completed |
NCT01845740 -
Phase Ib Study of SC Milatuzumab in SLE
|
Phase 1 | |
| Completed |
NCT02656082 -
Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT03178188 -
Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus
|
Phase 2/Phase 3 | |
| Terminated |
NCT02428309 -
Autologous Polyclonal Tregs for Lupus
|
Phase 1 | |
| Completed |
NCT01597050 -
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
|
Phase 2 | |
| Completed |
NCT01923415 -
A Non-drug Study Profiling Cutaneous Lupus
|
Phase 0 |